MedTrace Logo

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)

NCT03109080 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-24

No results posted yet for this study

Summary

A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.

Conditions

  • Breast Neoplasms, Triple-Negative
  • Breast Neoplasm Malignant Female
  • Radiotherapy Side Effect

Interventions

DRUG

Olaparib

five levels of dose, per os administration, twice daily each day

RADIATION

Radiation therapy

3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Institut Curie

    lead OTHER

Principal Investigators

  • Youlia KIROVA, MD · Institut Curie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-24
Primary Completion
2020-02-17
Completion
2021-11-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109080 on ClinicalTrials.gov